BioPath

Latest News
BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTSAug 15 2019
Bio-Path Holdings to Announce Second Quarter 2019 Financial Results on August 15, 2019Aug 8 2019
BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTSMay 16 2019
Bio-Path Holdings to Announce First Quarter 2019 Financial Results on May 16, 2019May 9 2019
Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019 --- Highlighting Important Cancer Gene, STAT3, Therapeutic Strategy in Pancreatic, Non-Small Cell Lung Cancers and Acute Myelogenous LeukemiaApr 3 2019
BIO-PATH HOLDINGS REPORTS FULL YEAR 2018 FINANCIAL RESULTS: Conference Call to be Held Today at 8:30 a.m. ETMar 20 2019
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019Mar 15 2019
Bio-Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common StockMar 14 2019
Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common StockMar 12 2019
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid LeukemiaMar 6 2019
Bio-Path Holdings to Present Data at the 2019 AACR Annual MeetingFeb 28 2019
Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-MarketJan 23 2019
Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-MarketJan 18 2019
Bio-Path Holdings Announces 1-for-20 Reverse Stock SplitJan 18 2019
Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common StockJan 17 2019
Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock (Pricing)Jan 15 2019
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock (Launch)Jan 15 2019
Bio-Path Holdings Provides Clinical Update and 2019 Business OutlookDec 27 2018
Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual MeetingDec 3 2018
BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTSNov 15 2018

More News

Giving Previously Untreatable Cancer Patients a Fighting Chance

We are developing targeted cancer treatments that offer effective therapy without harsh side effects so that even the most fragile patients can have tolerable treatment options.

About Us

DNAbilize^®

The company’s lead candidate is prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, for the treatment of acute myeloid leukemia (AML). Prexigebersen is being assessed in a Phase 2 trial in combination with front-line therapy.

Learn More

Our Patients

Prognosis for these older cancer patients remains very poor. Bio-Path aims to meet the need that exists for non-toxic therapies for older, fragile cancer patients who are unfit or ineligible for high-dose chemotherapy.

A new path in DNA-powered medicine.

Latest News

Giving Previously Untreatable Cancer Patients a Fighting Chance

DNAbilize^®

Our Patients

Our Products

Delivering a Better Path for Cancer Patients.

Latest News

Giving Previously Untreatable Cancer Patients a Fighting Chance

DNAbilize®

Our Patients

Our Products

Delivering a Better Path for Cancer Patients.

DNAbilize^®